Private company
Scioderm
American pharmaceutical company
Scioderm, acquired by Amicus Therapeutics in 2015, was a rare disease company focused on developing a treatment for Epidermolysis Bullosa (EB), a rare genetic disease characterized by extremely fragile skin and recurrent blister formation. There are currently no approved therapies for EB. Scioderm was developing a topical treatment known as SD-101, or Zorblisa, aimed at triggering wound reduction and closure, and a reduction in body surface area coverage of blisters and lesions.2 Wikipedia text CC BY-SA 4.0
Last updated Oct 21, 2026.
Overview
See how the biggest companies compare on our leaderboards
Scioderm, acquired by Amicus Therapeutics in 2015, was a rare disease company focused on developing a treatment for Epidermolysis Bullosa (EB), a rare genetic disease characterized by extremely fragile skin and recurrent blister formation. There are currently no approved therapies for EB. Scioderm was developing a topical treatment known as SD-101, or Zorblisa, aimed at triggering wound reduction and closure, and a reduction in body surface area coverage of blisters and lesions.2
Timeline
- 2012Founded Founded1
Links
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataScioderm on Wikidata
- 2WikipediaScioderm on Wikipedia